Dimerix acquires phase 2-ready kidney injury treatment DMX-652
MELBOURNE, Australia - Dimerix Limited (ASX:DXB) announced today it has acquired DMX-652, a drug candidate for acute kidney injury, from Mission Therapeutics Limited. The biotech company, with a market capitalization of $100.6 million, has seen its stock decline 55% over the past six months, currently trading at $0.17.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
MELBOURNE, Australia - Dimerix Limited (ASX:DXB) announced today it has acquired DMX-652, a drug candidate for acute kidney injury, from Mission Therapeutics Limited. The biotech company, with a market capitalization of $100.6 million, has seen its stock decline 55% over the past six months, currently trading at $0.17. The acquisition includes a composition of matter patent, an open U.S. Investigational New Drug application with an FDA-approved Phase 2 clinical trial protocol, and sufficient pharmaceutical grade drug product for the Phase 2 trial, according to a press release statement.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- MELBOURNE, Australia - Dimerix Limited (ASX:DXB) announced today it has acquired DMX-652, a drug candidate for acute kidney injury, from Mission Therapeutics Limited. The biotech company, with a market capitalization of $100.6 million, has seen its stock decline 55% over the past six months, currently trading at $0.17.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 8m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Dimerix acquires phase 2-ready kidney injury treatment DMX-652
Sources1TypeCoverageInvesting.com · Company News